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ABSTRACT
Trib2 pseudokinase has oncogenic and tumour suppressive functions depending 
on the cellular context. We investigated the ability of Trib2 to transform different 
haemopoietic stem and progenitor cells (HSPCs). Our study identified the granulocyte-
macrophage progenitor (GMP) subpopulation as a potent leukaemia initiating cell 
of Trib2-driven AML in vivo. Trib2 transformed GMPs generated a fully penetrant 
and short latency AML. AML cells expressing elevated Trib2 led to a chemoresistant 
phenotype following chemotherapy treatment. We show that Trib2 overexpression 
results in an increase in BCL2 expression, and high Trib2 expressing cells are highly 
sensitive to cell killing by BCL2 inhibition (ABT199). Combined treatment with 
chemotherapeutic agents and BCL2 inhibition resulted in synergistic killing of Trib2+ 
AML cells. Trib2 transformed GMP AML cells showed more chemoresistance compared 
with HSPC derived Trib2 AML cells associated with higher Bcl2 expression. There is 
significant correlation of high TRIB2 and BCL2 expression in patient derived human 
AML cells. These data demonstrate that the cell of origin influences the leukaemic 
profile and chemotherapeutic response of Trib2+ AML. Combined TRIB2 and BCL2 
expression in AML cells may have clinical utility relevant for monitoring drug 
resistance and disease relapse.
INTRODUCTION
Tribbles homolog 2 (TRIB2) pseudokinase functions 
as both an oncogene and a tumour suppressor with 
important roles in human health and disease. TRIB2 is 
involved in the aetiology of a number of cancers including 
acute leukaemia, melanoma, ovarian, lung and liver cancer 
[1]. While kinase activity has not yet been linked to the 
tribbles family of proteins (TRIB1, TRIB2 and TRIB3), 
they function via protein scaffolding to regulate signalling 
pathways including AKT and MAPK signalling, and to 
control protein levels via the proteasome including key 
cell differentiation and cell cycle regulators [2].
TRIB2 is thought to be the earliest evolved family 
member of the tribbles family [2]. It has been shown 
to have oncogenic and tumour suppressor activities in 
cancer cells, which appear to be dependent on the cellular 
context [1]. As an oncogene, Trib2 is capable of driving 
acute myeloid leukaemia (AML) that is dependent on the 
proteasomal degradation of the transcription factor C/
EBPα [3]. This function was also key to the oncogenic role 
of TRIB2 in lung cancer, and was shown to be mediated 
via scaffolding with the ubiquitin E3 ligases COP1 and 
TRIM21 [4, 5]. The modulation of AKT phosphorylation 
and expression of the cell cycle regulator CDC25C are 
also associated with the oncogenic activity of TRIB2 [6, 
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7]. In contrast, TRIB2 has tumour suppressor activities in 
acute leukaemia, linked with aberrant MAPK signalling 
that resulted in tumour cell death [8–10].
TRIB2 expression has been reported as a biomarker 
for diagnosis and progression of cancers including 
melanoma [11]. For leukaemia, TRIB1, TRIB2 and TRIB3 
expression associates with a number of the different 
subgroups of AML; TRIB1 is both mutated and elevated in 
acute megakaryocytic leukaemia (AMKL) and AML with 
8q amplifications [12–14]; TRIB2 expression associates 
positively with the AML subset with dysregulated CEBPA 
[15, 16] and negatively with subgroups with a high 
frequency of mutated NPM1 and FLT3, however TRIB2 is 
high in AML with FLT3TKD [10, 17]. TRIB3 expression 
associates positively with APL disease progression [18, 
19]. TRIB2 (and TRIB1) expression promotes AML in 
HOX-dependent leukaemias [16, 20–22], and in acute 
promyelocytic leukaemia (APL) [23]. Thus, TRIB proteins 
represent promising leukaemia biomarkers and therapeutic 
targets in AML.
AML cells comprise a heterogeneous population 
arranged in a hierarchical manner with a small number 
of leukaemia stem cells (LSCs) responsible for initiating 
and maintaining the disease, and which are the cause of 
drug resistance and disease relapse [24]. It is hypothesised 
that the cell of origin or leukaemia initiating cell (LIC) 
may influence disease progression, LSC phenotype 
and response to therapy. Comparing AML LSCs with 
their normal counterparts, studies have indicated 
that LSC activity occurs in cells not only within the 
hematopoietic stem cell (HSC) compartment but also in 
multipotential progenitors (MPPs) or more committed 
myeloid progenitors (common myeloid progenitors 
(CMPs), granulocyte-macrophage progenitors (GMPs)). 
In human AML, LSC activity can be found not just in 
the CD34+CD38- cell, but also present with the lowest 
frequency in the more mature CD38+ fraction [25–
28]. However, cellular heterogeneity exists within the 
LSC fraction, and LSCs also exhibit plasticity. Thus 
characterising the LSC population does not identify 
the original cell that gave rise to the leukaemia. It has 
been clearly demonstrated that cells other than HSCs 
acquire LSC properties when transformed by appropriate 
oncogenes, which are characterized by their ability to 
transfer self-renewal potential to cells at committed stages 
of differentiation [29–34]. When ectopically expressed in 
hematopoietic stem and progenitor cell (HSPC) enriched 
bone marrow (BM) cells, Trib2 was shown to induce 
AML in a murine transplant model [3]. It remains unclear 
whether the LIC in a Trib2+ leukaemia is a HSC or a more 
committed progenitor cell.
Our current study identified the LIC in Trib2+ 
AML. Expression of Trib2 in the GMP cell drove 
a highly penetrant disease with a short latency in 
a murine transplant model. To address whether the 
chemotherapeutic response is affected by Trib2 expression 
and the nature of the LIC, we assessed the response of 
Trib2+ AML cells to chemotherapeutic agents used 
commonly in AML treatment. We provide evidence for 
a TRIB2 role in chemoresistance via elevation of BCL2 
expression and reveal synergistic cell killing following 
co-treatment with BCL2 inhibition and standard 
chemotherapeutic drugs. Our results highlight that using 
TRIB2 as a biomarker, we can identify AML cells with 
a heightened sensitivity to combined BCL2 inhibition 
and chemotherapy, thus providing a novel therapeutic 
approach for treating TRIB2+ AML.
RESULTS
Trib2 can transform HSCs, MPPs, CMPs, GMPs 
and MEPs in vitro
To identify the cell of origin in murine Trib2+ 
leukaemias, an in vitro approach was first utilised. Several 
studies have explored the LIC of specific oncogenes using 
either a methylcellulose-based serial replating assay and/or 
retroviral-mediated murine bone marrow transplantation 
(BMT) [29–34]. Purified stem and progenitor cells, 
including HSCs, MPPs, CMPs, GMPs and megakaryocyte-
erythroid progenitors (MEPs), transduced with a GFP-
tagged lentiviral vector encoding Trib2, were seeded 
in methocult supplemented with cytokines that induce 
myeloid differentiation (Figure 1A). Following the first 
plating round (P1), GFP+ cells were sorted and serially 
replated. The ability of cells to form colonies by the third 
replating in this assay implies acquisition of self-renewal 
ability and increased proliferation. The cells were serially 
replated to P5, and colonies and cells were analysed from 
P3 to P5. Control transduced cells are unable to replate 
[4]. All Trib2 transduced populations were efficiently 
producing colonies at P3, and these cells still formed 
colonies by P5, however different efficiencies between 
groups were observed (Figure 1B). By P5, CMP derived 
cells were producing very few smaller sized colonies 
(Figure 1C). Trib2 transduced GMP derived cells also 
produced smaller sized colonies, while MPP derived 
cells produced the largest sized colonies. Colonies were 
also categorised based on their morphology as described 
previously [34] and were of 3 distinct phenotypes: Type 
I, Type II and Type III. Type I colonies contain immature 
myeloid precursor cells and compact in size, Type II 
colonies contain more mature cells and have a compact 
centre surrounded by a diffuse halo of cells, while type 
III colonies are the most differentiated and comprise 
dispersed cells with no core. Immature Type I colonies 
were well represented on transformed HSC, MPP, GMP 
and MEP plates, comprising 25-50% of colonies by P3 
but much fewer on CMP plates (Figure 1D and 1E). The 
intermediate Type II colonies were rarely observed in 
Trib2 transduced CMPs or GMPs, being most prominent 
on transformed MPP plates, as well as HSC and MEP 
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plates. Interestingly, while type III (mature) colonies 
were present on all plates, they were predominantly on 
CMP and GMP plates with CMP plates being primarily 
composed of type III colonies. Cytospins of the cells 
demonstrated that Trib2 transduced HSC, MPP, GMP and 
MEP derived colonies contained many undifferentiated 
cells with a high nucleus/cytoplasm ratio, while CMP 
derived colonies contained very few undifferentiated cells, 
with almost all cells showing evidence of granulocytic or 
monocytic differentiation (Figure 1F).
It was next determined if the differences in colony 
size and shape, and cellular morphology correlated with 
cell surface marker changes. Flow cytometric analysis of 
P3 and P5 cells revealed that HSCs, MPPs and MEPs had 
similar CD11b and Gr1 expression, both the CMP and 
GMP derived colonies trended toward lower CD11b and 
higher Gr1 (Figure 1G-1I). CD11b and Gr1 expression 
increased slightly in HSC and MPP derived cells as the 
cells were replated to P5, likely because the time taken 
to mature from these hierarchical stem populations. There 
was high cKit expression, a marker of cell immaturity, in 
almost all populations at each plating, although less than 
50% of MPP derived cells expressed cKit by P5 (Figure 
1J and 1K). Analysis of CD11b and Gr1 expression was 
performed through the cKit+ and cKit- gates which showed 
no CD11b expression and low Gr1 expression on cKit+ 
cells, while as expected the cKit- cells expressed mature 
myeloid markers (Supplementary Figure 2A and 2B). The 
high levels of cKit expression observed in HSC, CMP, 
GMP and MEP derived Trib2 transduced cells correlates 
well with published data showing Trib2-induced AML 
cells are cKit+ [3]. Together these data show that Trib2 
can transform stem and progenitor populations in vitro 
with different efficiencies, and the resultant transformed 
colonies and cell types differ depending on the cell of 
origin. The data shows that Trib2 has conferred both 
self-renewal ability and a differentiation block to HSCs, 
GMPs and MEPs. While Trib2 transduced MPPs also 
displayed self-renewal ability, by P5 there was a large 
population of cKit- cells still present which express the 
myeloid differentiation markers CD11b and Gr1. These 
data indicate that the Trib2 LIC potentially resides in 
either the HSC or GMP as only these populations display 
pre-leukaemic characteristics in vitro.
Trib2 propagates a fully penetrant and short 
latency AML from the GMP in vivo, but not the 
HSC, MPP or CMP
The results from the serial replating assay indicated 
that Trib2 conferred replating and self-renewal capacity 
to the HSC, MPP, CMP, and GMP populations. Despite 
this, Trib2 was unable to efficiently block differentiation 
in the MPP and to fully transform the CMP derived cells. 
In order to resolve these observations and to elucidate the 
leukaemia initiating potential of the stem and progenitor 
populations, a BMT was performed. By P3 of the serial 
replating assay all populations were exhibiting hallmarks 
of pre-leukaemic cells i.e. efficiently producing colonies, 
high cKit expression and low expression of mature myeloid 
markers. Thus the CD45.2+ cells from P3 HSC, MPP, 
CMP and GMP derived colonies were transplanted into 
sublethally irradiated CD45.1+ C57BL/6 recipient mice and 
transplanted animals were monitored for 1 year (Figure 2A).
Peripheral bleeds (PB) were taken at 7 weeks post-
transplant and the levels of engraftment were determined 
by quantifying CD45.2 expression in the blood (Figure 2B). 
Cells transplanted from HSC and GMP derived colonies 
displayed high levels of engraftment. Cells transplanted 
from MPP-derived colonies showed no engraftment in 
the recipient mice, while only 1 of 5 CMP transplanted 
mice displayed engraftment in the PB at 7 and 16 weeks 
post-transplant. The MPP and CMP transplanted mice that 
displayed no engraftment in the PB were culled at 16 weeks 
post BMT and all had normal white blood cell (WBC) 
counts, normal spleen weights, and normal percentages of 
circulating neutrophils, lymphocytes, monocytes, eosinophils 
and basophils (Supplementary Figure 3A-3C). All mice 
transplanted with GMP derived cells succumbed to disease 
with a median latency of 14 weeks (Figure 2C and Table 1). 
This is significantly shorter than AML disease developed 
from HSPC (5FU or cKit enriched) BM cells previously 
reported which had a median latency of 26 weeks [3]. Of 
the cohort transplanted with HSC derived cells, only 1 of 4 
mice developed disease within 1 year, with a latency of 26 
weeks. Further analysis of the mice that displayed peripheral 
engraftment but did not develop leukaemia within 1 year, 
showed no disruption to haemopoiesis with normal spleen 
weights, WBC counts and normal percentages of circulating 
neutrophils, lymphocytes, monocytes, eosinophils and 
basophils (Supplementary Figure 3D-3F). The leukaemias 
generated from Trib2 transduced GMP derived cells were all 
AMLs, identified as CD11b+Gr1+ cells (Figure 2D and 2E) 
and a lack of expression of B and T cell markers. Analysis 
of the absolute cell numbers in the BM and PB of mice with 
disease demonstrated that mice transplanted with Trib2 
transduced GMPs had elevated myeloid blast cells compared 
to the HSC transplanted mouse (Figure 2E). The sole HSC 
derived disease had a longer latency and a phenotype that 
was different from that of the GMP. BM cells of the HSC 
transplanted mouse had some CD11b expression with little to 
no Gr1 expression, and almost all cells expressing the B cell 
marker B220, but not CD19, and a fraction of cells expressing 
the T cell marker CD8 but not CD4 (Figure 2D and data not 
shown). These data show that Trib2 cannot induce leukaemia 
from MPPs or CMPs in vivo. Leukaemia is generated from 
the HSC and GMP in vivo, with different efficiencies, and has 
the ability to generate different types of leukaemia depending 
on the cell of origin. A uniformly myeloid disease with 100% 
penetrance was generated from the Trib2 transduced GMPs 
(leukaemic GMP or L-GMP) identifying the GMP as a potent 
Trib2 LIC.
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Figure 1: Trib2 transforms all HSPC populations with varying efficiency and immunophenotypes. (A) Schematic 
overview of CFC experiments. Murine BM cells were isolated and sorted for HSC, MPP, CMP, GMP and MEP populations. Following 
transduction the Trib2 expressing cells were plated in M3434 methylcellulose media 24hrs later. After 7 days (P1) colonies had formed, 
cells were sorted for GFP expression and GFP+ cells were serially replated to P5. Colonies and cells were analysed at P3, P4 and P5. (B) 
Average number of colonies at each replating normalised to GFP expression. Averages are of 2 independent experiments each with 3 
technical replicates shown +/− SD. (C) Average number of cells produced at each replating. Averages are of pooled triplicate plates from 
2 independent experiments +/− SD. (D) Representative images of colony types at P3 under 4x magnification (top) and 2x magnification 
(bottom). (E) Distribution of colony types at P5. Bars represent the average of 2 independent experiments each with 3 technical replicates 
+/− SD. (F) Cellular morphology of Trib2 transformed stem and progenitor cells. Cells from P3 colonies were spun onto glass slides using a 
cytocentrifuge and stained with the KwikDiff staining system. Representative images are shown, taken under 40X magnification. (G) Cells 
from each replating were stained for CD11b and Gr1 and analysed by flow cytometry. Representative flow cytometric analysis of GFP+ 
Trib2transformed stem and progenitor cells from P3 and P5. Graphs represent the average percentage expression of CD11b (H) and Gr1 (I) 
of GFP+ Trib2transformed stem and progenitor cells from P3, P4 and P5. Data represent the average of 2 independent experiments +/− SD. 
(J) Representative flow cytometric analysis of GFP+ Trib2 transformed stem and progenitor cells from P3 and P5 for cKit expression. (K) 
Graphs represent the average percentage expression of cKit on GFP+ Trib2 transformed stem and progenitor cells from P3, P4 and P5. Data 
represents the average of 2 independent experiments +/− SD.
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Trib2 expression mediates sensitivity to AML 
chemotherapy
The LSC is thought to be the cell that evades 
chemotherapy and drives relapse. To study the response of 
cells expressing elevated Trib2 to AML chemotherapeutic 
drugs, we used NB4, HL60 and U937 human AML cell 
lines. Cells were transduced with control empty vector 
(MigR1 retrovirus or PHR lentivirus) or with MigR1 
Trib2 or PHR Trib2, followed by treatment with increasing 
concentrations of cytarabine (Ara-C), doxorubicin 
(DOX) or daunorubicin (DNR) (both DOX and DNR 
are anthracyclines that can be used interchangeably), 
and etoposide (Etop). Analysis of cell viability showed 
that Trib2 overexpressing cells were significantly more 
resistant to the chemotherapeutic agents compared to 
Figure 2: Trib2 transformed GMPs drive AML with full penetrance and short latency. (A) Schematic overview of 
transplantation model used to identify the Trib2 LIC. CD45.2+ sorted HSCs, MPPs, CMPs, and GMPs were transduced with Trib2 lentivirus 
and plated in M3434 methylcellulose media after 24hrs. After replating to P3, cells were transplanted into sub-lethally irradiated CD45.1+ 
recipient mice. (B) Peripheral bleeds were taken at 7 weeks post BMT and analysed by flow cytometry for CD45.2 donor cell expression. 
Each dot represents percentage CD45.2 expression in the PB of an individual mouse, HSC (n=4), MPP (n=2), CMP (n=5), GMP (n=4). (C) 
Kaplan-Meier survival curve of mice reconstituted with cells derived from Trib2 transduced HSCs (n=4), MPPs (n=2), CMPs (n=5) and 
GMPs (n=4). *P=0.0171 by Log-rank test. (D) Absolute numbers of CD11b+Gr1+ cells in the BM (top) and PB (bottom) of Trib2 transduced 
HSC transplanted (n=1) and GMP transplanted (n=4) leukemic mice. Box and whiskers plot with whiskers denoting min to max, and line 
representing mean values. Dashed box denotes normal range in healthy mice as determined by HemaVet 950FS reference intervals (PB) 
and previously published data (BM). (E) Representative flow cytometric analysis of mature myeloid (CD11b, Gr1), in the BM, spleen and 
PB of Trib2 transformed GMPs (L-GMPs). Data is representative of n=4 GMP mice.
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control cells (Figure 3A-3C). Assessment of apoptosis 
using Annexin V/DAPI staining confirmed that elevated 
Trib2 expression reduced early (Annexin V+/DAPI-) 
and late apoptosis (Annexin V+/DAPI+) following drug 
treatment (Figure 3D and 3E). To address if cell death 
was being evaded as a result of an effect of Trib2 on 
cell proliferation, we measured the number of cells that 
remained in mitosis followed drug treatment. Drug treated 
Trib2 expressing cells were able to evade apoptosis and 
continue to undergo mitosis compared to control treated 
cells (Figure 3F and 3G). As previously published, loss of 
Trib2 in AML cells results in cell growth inhibition and G1 
cell cycle arrest [35]. Still, with lentiviral mediated loss 
of Trib2 expression in U937 cells, we observed increased 
cell death in response to drug treatment when normalised 
to untreated cells (Figure 3H). Together these data show 
that human AML cells expressing high levels of Trib2 are 
resistant to chemotherapeutic drug treatments.
Trib2 expression increases BCL2 expression 
which contributes to Trib2-mediated 
chemoresistance
Drug resistance as a result of continued proliferation 
and an inability to undergo apoptosis has been linked to 
levels of the BCL2 family of apoptotic regulators [36]. 
We therefore measured the expression levels of BCL2 
in Trib2 overexpressing cells. BCL2 gene and protein 
levels were highly upregulated in human AML U937 cells 
transduced with Trib2 compared to control cells (Figure 
4A and 4B). Anti-apoptotic BCL2 proteins reside on the 
outer mitochondrial membrane and prevent apoptosis 
by inhibiting the activation of the pro-apoptotic family 
members BAX and BAK. We confirmed that Trib2 leads 
to the elevation of mitochondrial BCL2 levels (Figure 
4C) conferring an anti-apoptotic phenotype on Trib2 
expressing cells. In addition to elevated BCL2, Trib2 
overexpression lead to trending increases in anti-apoptotic 
and pro-survival expressing genes MCL1 and XIAP (Figure 
4D), although protein levels of MCL1 were not affected 
(Figure 4B). We also observed trending decreases in pro-
apoptotic genes BID3, BAX and BCL2L11 but these were 
not significant (Figure 4D). To directly assess whether 
the increase in BCL2 expression by Trib2 contributed 
to the resistance to chemotherapy, we first assessed the 
sensitivity of control and Trib2 overexpressing cells to 
the BCL2 inhibitor ABT199, a BH3 mimetic [36]. Cells 
overexpressing Trib2 were more sensitive to death induced 
by BCL2 inhibition alone compared to control cells (Figure 
4E). Next, we determined the ability of BCL2 inhibition 
to sensitize Trib2 expressing AML cells to chemotherapy. 
Combination treatment of ABT199 and DNR significantly 
reduced the survival of Trib2 overexpressing human AML 
cells compared to DNR treatment or BCL2 inhibition 
alone and compared to control cells (Figure 4F). We used 
the Chou-Talalay method to calculate the combination 
Table 1: Summary table of the outcome of the in vivo leukaemogenesis experiment, specifying the cells of origin 
(column 1), donor cells (column 2), disease outcome (column 3), disease latency (time to death column 4) and mean 
time to disease in the last column
Immunophenotype of the 
transduced cells
Input BM Phenotype of the 
Leukemia arising
Time to death 
(Weeks)
Mean time to AML 
+/− SD (weeks)
Lin-cKit+Sca1-CD34+CD16/32hi GMP MiGR1 TRIB2 Myeloid 10
14 +/− 8 weeks
Lin-cKit+Sca1-CD34+CD16/32hi GMP MiGR1 TRIB2 Myeloid 10
Lin-cKit+Sca1-CD34+CD16/32hi GMP MiGR1 TRIB2 Myeloid 10
Lin-cKit+Sca1-CD34+CD16/32hi GMP MiGR1 TRIB2 Myeloid 26
Lin-cKit+Sca1-CD34+CD16/32+ CMP MiGR1 TRIB2 No disease 16
N/A
Lin-cKit+Sca1-CD34+CD16/32+ CMP MiGR1 TRIB2 No disease 16
Lin-cKit+Sca1-CD34+CD16/32+ CMP MiGR1 TRIB2 No disease 16
Lin-cKit+Sca1-CD34+CD16/32+ CMP MiGR1 TRIB2 No disease 16
Lin-cKit+Sca1-CD34+CD16/32+ CMP MiGR1 TRIB2 No disease 49
Lin-cKit+Sca1+CD150-CD48- MPP MiGR1 TRIB2 No disease 16
N/A
Lin-cKit+Sca1+CD150-CD48- MPP MiGR1 TRIB2 No disease 16
Lin-cKit+Sca1+CD150+CD48- HSC MiGR1 TRIB2 Mixed lineage 26 26 weeks
Lin-cKit+Sca1+CD150+CD48- HSC MiGR1 TRIB2 No disease 49
N/ALin-cKit+Sca1+CD150+CD48- HSC MiGR1 TRIB2 No disease 49
Lin-cKit+Sca1+CD150+CD48- HSC MiGR1 TRIB2 No disease 49
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Figure 3: Trib2 overexpressing cells are chemotherapy resistant.  Cell viability of (A) NB4 (B) HL60 (C) U937 overexpressing 
Trib2 cells, in response to increasing doses of cytarabine (Ara-C), Doxocyline (Dox), daunorubicin (DNR) and Etoposide (Etop) after 
24hr, determined by Trypan blue exclusion. (D) Representative apoptosis profile of DNR treated U937 cells transduced with Trib2 or PHR 
empty vector for 24hr; live, DAPI−Annexin V−; early apoptotic, DAPI− Annexin V+; late apoptotic, DAPI+ Annexin V+. (E) Graph of 
the average fold change in cells positive for Annexin V, in U937 cells transduced with Trib2 or PHR empty vector and treated with DNR 
for 24hr, from 3 independent experiments. Error bars denote +/− SEM. (F) Representative mitosis FACS profile of DNR treated U937 cells 
transduced with Trib2 or PHR empty vector for 24hrs. (G) Graph of fold change in mitotic index (MI), following treatment with DNR 
for 24hr and normalized to untreated control sample. Error bars denote +/− SEM. (H) U937 cells were transduced with control pLKO.1 
or pLKO.1 shTrib2 lentivirus and treated with cytarabine (Ara-C), daunorubicin (DNR) and etoposide (Etop). Fold change in cell death 
(Annexin+ and/or DAPI+ cells) was determined after 24hrs. Bars represent the average of 2 independent experiments each with 3 technical 
replicates. Error bars denote +/− SEM.
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index (CI), whereby the drugs are added in a given ratio 
and the CIs calculated using CompuSyn software to give 
an indication of synergism, where CI<1 is synergism, 
CI=1 is additive, and CI>1 is antagonism. These results 
revealed significant synergism between BCL2 inhibition 
and DNR treatment in Trib2 expressing human AML cells 
(Figure 4G).
High TRIB2 and BCL2 expression correlate and 
contribute to a drug resistance phenotype
To determine whether AML generated in vivo from 
Trib2 overexpression similarly led to a chemoresistant 
profile, we studied the effect of drug treatment (Ara-C, 
Dox/DNR and etoposide) on AML cell viability. Murine 
AML cells derived from Trib2 expression in cKit 
enriched haemopoietic stem and progenitor cells (HSPCs, 
which contain HSCs, MPPs, CMPs and GMPs) were 
significantly more resistant to the chemotherapeutic drugs 
than control transduced cells (Figure 5A). We then asked 
whether the Trib2 L-GMP that was capable of driving a 
fully penetrant and short latency AML  in vivo, exhibited 
drug resistance. In comparison to the in vitro transformed 
HSCs and GMPs, in vivo derived AML cells from Trib2 
transformed GMPs displayed significant resistance to 
AML chemotherapeutic drugs (Figure 5B). We have then 
correlated high Bcl2 expression with drug resistance in 
the Trib2 L-GMP. High levels of Bcl2 expression were 
observed in Trib2 L-GMP cells compared to Trib2 AML 
cells generated from an HSPC enriched population (Figure 
5C). When we compared Bcl2 expression in Trib2 L-GMP 
cells with cells from the single HSC derived disease 
(L-HSC), we also observed higher Bcl2 expression in the 
L-GMPs and this correlated with higher Trib2 expression 
(Figure 5D). We then correlated high BCL2 expression and 
high TRIB2 expression in human AML by interrogation 
of a publically available human AML dataset [37]. 
Analysis of samples within the top 25 percentile of TRIB2 
and BCL2 expression showed a significant correlation 
of TRIB2 and BCL2 expression (Figure 5E). These data 
indicate that the GMP population is readily transformed 
by Trib2 and is highly drug resistant correlating with high 
BCL2 expression. Together, these data indicate the GMP 
as the potential LSC in AMLs expressing high levels 
of Trib2. Monitoring patients for a high TRIB2/BCL2 
expressing cell may identify patients that may benefit 
from combination BCL2 inhibition and chemotherapy, 
and provide further information on patients at risk for 
chemotherapy resistance and disease relapse.
DISCUSSION
Our study has identified the GMP as a potent LIC 
for the pseudokinase Trib2. Trib2 transformed GMPs 
produced a fully penetrant myeloid leukaemia with fast 
kinetics and an immunophenotype consistent with a 
maturing myeloid cell (L-GMP). We report that the Trib2 
L-GMP is a highly drug resistant cell, evading cell death 
induction by commonly used AML chemotherapeutic 
drugs. Due to the increase in BCL2 expression, mediated 
by high Trib2 expression, Trib2+ AML cells can be 
sensitized to standard chemotherapies by combined 
treatment with BCL2 inhibition. In 2016, the US Food 
and Drug Administration (FDA) approved the use of the 
BCL2 inhibitor ABT199 (Venetoclax, Venclexta®) for 
the treatment of patients with CLL with 17p deletion. In 
July 2017, the US FDA granted breakthrough therapy 
designation for Venclexta® in combination with low 
dose cytarabine (LDAC) for elderly patients with 
previously untreated AML who are ineligible for intensive 
chemotherapy. We have provided evidence allowing for 
the identification of AML cells that would be targeted by 
this treatment and potentially patients that would benefit 
from this clinical strategy.
Trib2 overexpression was able to confer self-
renewal and proliferative capacity on stem and progenitor 
populations in vitro but the cell of origin affected the 
number, size and morphology of colonies and cells 
produced. However, in vivo Trib2 was only able to initiate 
leukaemia with potency from the GMP, with incomplete 
penetrance from the HSC, and not at all from the CMP 
and MPP. The median latency of the GMP derived 
disease was just 14 weeks while the latency of the HSC 
derived disease was significantly longer at 26 weeks. It is 
possible that the GMP disease may have enriched for the 
Trib2 LIC compared to the slower HSC derived disease, 
although if this was true then a more penetrant disease 
should have been observed with the HSC derived cells. 
Previous studies support that the LIC can be enriched in 
the HSC [25, 27, 30] or a more mature myeloid progenitor 
population such as the GMP [28, 33, 38–40] and that 
the identity of the LIC can affect the disease latency. A 
study of primary AML samples showed that LSC activity 
was enriched in subsets which phenotypically resembled 
murine LMPPs and GMPs [28]. When examined at 
the molecular level the leukaemic LMPPs and GMPs 
resembled their normal counterparts suggesting that the 
LIC was a committed progenitor cell as opposed to a HSC 
with aberrant surface marker expression.
Our data suggest that distinct mechanisms of Trib2 
leukaemogenesis exists dependent on the cell of origin 
being a HSC or GMP. Endogenous Trib2 expression is 
higher in the HSC compared to the GMP (Supplementary 
Figure 1A and 1B), and in our overexpression model we 
achieved high Trib2 expression in the HSC and the GMP 
following transduction (Supplementary Figure 1D). The 
highly penetrant disease generated by Trib2 expression in 
the GMP may be attributable to the expression levels of 
lineage specific genes. C/EBPα is essential for the CMP 
to GMP transition and its expression is highest in the 
GMP (Supplementary Figure 1C), and as Trib2 degrades 
C/EBPα to drive AML disease [3, 4], this may account for 
Oncotarget14985www.oncotarget.com
the potent transformability of the GMP. Indeed, our recent 
work has also shown that in the absence of C/EBPα, Trib2 
in unable to generate AML disease [41]. Recent studies 
have put forward an interesting hypothesis that myeloid 
differentiation is required for the formation of LSCs 
and for AML initiation [42]. The authors showed that 
Figure 4: Trib2 overexpression increases BCL2 expression and sensitises to BCL2 inhibition-induced cell death.  (A) 
Graph represents fold change (2-ddCt) of BCL2 gene expression in Trib2 over expressing U937 cells relative to empty vector control. ABL 
was used as the house keeping gene. Bars represent average of n=3. Error bars denote +/− SEM. For statistical analysis an unpaired, two-
tailed, student t-test was performed. (B) Western blot analysis of whole cell lysates from U937 expressing PHR Trib2 or control PHR cells 
for Trib2, BCL2, MCL1 and β-ACTIN (loading control) expression. Representative blot of 2 biological replicates. (C) Western blotting 
analysis of fractions enriched for Mitochondria (M) and cytoplasmic (C) from U937 expressing PHR Trib2 or control PHR cells for 
BCL2 and Trib2. HSP70 and TOMM20 used as controls for cytoplasm and mitochondrial separation. Representative blot of 3 biological 
replicates. (D) Real time PCR was performed in U937 expressing PHR Trib2 or PHR control cells for the indicated genes. Gene expression 
was normalised to housekeeping gene ABL. Gene expression in PHR Trib2 cells was plotted relative to PHR cells, represented by –ddCt or 
Log2 fold change. Data represents the average of 3 independent experiments. (E) Cell viability of U937 expressing PHR Trib2 or control 
PHR cells in response to increasing doses of ABT199 after 24hr, determined by Annexin V and DAPI stained cells. Cells Annexin V- and 
DAPI- were plotted as normalized percentage of cells to untreated control. An average of 3 biological replicates was plotted as an xy scatter 
plot as a dose response curve. Error bars denote +/− SEM. (F) Bar chart presentation of cell viability of PHR and PHR Trib2 expressing 
U937 cells in response to the indicated concentrations of DNR and ABT199 determined by FACS based analysis of Annexin V and DAPI 
stained cells. Cells Annexin V- and DAPI- were plotted as normalized percentage of cells to untreated control. Average of 2 independent 
experiments graphed with error bars denoting +/− SEM, and statistical significance determined by student t test. (G) Table depicting various 
drug combination treatments of U937 expressing PHR Trib2 cells, ratio of the drug concentrations (DNR:ABT199), fraction effected 
(represented by cells undergoing apoptosis or cells Annexin V+, determined by FACS), combination index values generated by CompuSyn 
software and the extent of synergism as indicated by the numerical value of Combination Index (CI). Data is representative of 3 independent 
experiments. CI values were plotted against Fa (fraction affected).
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leukaemia could be restored in Cebpa deficient cells by 
treating cells with myeloid cytokines, thus demonstrating 
that it was not loss of C/EBPα itself, but rather impaired 
myelomonocytic differentiation which prevented 
leukaemia initiation. Therefore, the differentiation state of 
the cell of origin may determine the leukaemic potential 
of cells with elevated Trib2 expression and our data would 
support this. However, the ability of Trib2, and other 
Figure 5: Trib2 L-GMP is highly drug resistant with correlation of high TRIB2 and BCL2 expression.  Cell viability of 
AML cells derived from Trib2 transduced HSPCs (A) and Trib2 transduced HSC and GMP CFC3 cells, and AML cells (L-GMPs) derived 
from Trib2 transduced GMPs (B), following treatment with the indicated concentrations of Ara-C and DNR and assessed for live cells 
at 24hours by trypan blue exclusion. (C) Transcript expression of Bcl2 in Trib2 L-GMPs and HSPC Trib2 AML cells determined by real 
time PCR. HPRT1 housekeeping gene was used to normalise the gene expression. Each data point represents an individual mouse in the 
respective arm. P<0.05 determined by student t test. Error bars represent +/− SEM. (D) Gene expression analysis of Trib2 and Bcl2 in Trib2 
L-GMP (n=4) and L-HSC (n=1) cells determined by real time PCR. HPRT1 housekeeping gene was used to normalise gene expression. 
Bars represent average of group and error bars represent +/− SEM. (E) Venn diagram showing a strong expression correlation between 
TRIB2 and BCL2 expression, generated by filtering AML samples from the MILE study. p≤ 0.0001, empirically assessed after 10,000 
Monte Carlo simulations.
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oncogenes, to generate leukaemia from functionally and 
phenotypically distinct stem and progenitor populations 
also suggests that there are overlapping gene expression 
signatures initiated by different oncogenes which facilitate 
leukaemic transformation [31]. Gene expression analysis 
has revealed many shared pathways between HSCs and 
LSCs [43], thus suggesting that oncogenes switch on stem 
cell transcriptional programs. Purification of the LSC 
compartment in an MLL-AF9 mouse model has indicated 
that at the molecular and phenotypic level the MLL-AF9 
LSC closely resembled a more committed progenitor 
cell, the GMP which also expressed HSC specific genes 
[30]. However, the phenotype of LSCs in established 
leukaemias may be determined by the oncogenic event 
rather than reflecting the phenotype of the originating cell, 
and thus the phenotype of LSCs may not be indicative of 
the cell of origin. Indeed using a conditional inducible 
genetic model, it has been shown that disease developed 
by MLL-AF9 expression in a HSC results in a more 
aggressive phenotype compared to expression in the GMP 
[44]. Other studies have isolated HSCs and HSPCs and 
retrovirally introduced oncogenes in these cells to identify 
the cells of origin. Specific fusion oncoproteins found in 
human AML patients MLL-ENL, MLL-AF9, MLL-GAS7, 
BCR-ABL and MOZ-TIF2 can transform HSCs, CMPs 
and/or GMPs [29, 32, 45]. In summary, studies support our 
conclusion that the GMP, with its inherent differentiation 
state and gene expression signature, is a more potent LSC 
following Trib2 expression compared to other progenitors.
We have identified that Trib2 leads to increased 
BCL2 expression, an anti-apoptotic and pro-survival gene 
that is therapeutically targetable, and associated with drug 
resistance across multiple cancers [46]. The expression 
of apoptotic proteins in AML is highly heterogeneous, 
and intrinsic to the disease pathology. High levels of 
BCL2 have been shown to be associated with a poorer 
survival and treatment resistance [47]. The potential of 
BCL2 as a therapeutic target is already well recognised. 
Present day clinical trials are largely focusing on the 
second generation, selective BH3 mimetic ABT199, as 
the early generation inhibitors have been limited by 
thrombocytopenia [48]. As a single agent only a small 
number of AMLs are susceptible, thus combination 
therapies are being pre-clinically and clinically assessed 
e.g. combination with LDAC, kinase inhibitors, 
hypomethylating agents, Mcl1 and mdm2 inhibitors [49] 
(e.g. NCT02203773, NCT02427451). The sensitivity to 
the BCL2 inhibitor ABT199 positively correlates with 
endogenous BCL2 protein level and negatively correlates 
with BCL-XL protein level in AML cell lines.
Our work has shown that BCL2 expression is 
upregulated by Trib2 and contributes to a chemoresistant 
phenotype highlighting that combination treatment with 
chemotherapy and BCL2 inhibition would overcome 
this drug resistance. Previously it has been shown 
that overexpression of Trib2 in Me-1 cell line led to 
dephosphorylation of BCL2 associated with an apoptotic 
response [10], and that BCL2 overexpression could rescue 
the apoptosis induced by Trib2 overexpression in TF-1 cell 
line [50], however total endogenous BCL2 levels or other 
BCL2 family members were not reported. In contrast, 
BCL2 overexpression could rescue apoptosis induced by 
Trib2 knockdown in T-ALL cell lines [51], which is in line 
with our previous data that Trib2 knockdown in AML cells 
also induced apoptosis [35] and with our current findings. 
The difference in the response of AML cells to TRIB2 
overexpression between the former studies and ours may 
be explained by the balance of pro- and anti-apoptotic 
BCL2 family members endogenous expression in the AML 
cell lines used. We have shown in our study that Trib2 
induced expression of BCL2 but does not affect MCL1 
expression. One possible mechanism for the induction of 
BCL2 expression by Trib2 is through C/EBPα and NF-
κB. C/EBPα p42 and p30 have been shown to cooperate 
with NF-κB p50 to induce Bcl-2 transcription, and CEBPA 
and Bcl-2 RNA levels correlate highly in human AMLs 
[52]. While Trib2 overexpression degrades C/EBPα p42 to 
induce AML, it also results in an increase in the truncated 
p30 isoform of C/EBPα, and this increase may contribute 
to the increase in BCL2 expression observed. Considering 
the fact that endogenous levels of C/EBPα are much 
higher in the GMP than the HSC, this may also account 
for the comparatively low levels of BCL2 observed in the 
L-HSC cells.
The oncogenic activity of TRIB2 has been linked to 
its role in the block of myeloid differentiation, degradation 
of key myeloid transcription factors and cell cycle 
regulators, and pro-survival mechanisms. In contrast, 
studies have revealed tumour suppressor functions of 
Trib2, including pro-apoptotic and reduced MAPK 
signalling. These opposing functions have been described 
in acute leukaemia. Elevated levels of Trib2 drive a 
potent AML disease in murine models and associate 
with a specific subgroup of human AML, both human 
and mouse models are linked to the C/EBP transcription 
factor family. The knockdown of TRIB2 leads to cell cycle 
arrest and apoptosis of the cancer cells [3, 35, 51, 53]. In 
contrast, low levels of TRIB2 associate with human AML 
with high NPM1 and FLT3ITD mutation frequency and 
in some cell types, elevated TRIB2 drives apoptosis [10, 
50]. High levels of TRIB2 have been associated with drug 
resistance to standard therapies and PI3K inhibitors in a 
number of solid cancers [6], whereas low levels of TRIB2 
expression have been associated with drug resistance in 
ovarian cancer patients [54]. These conflicting roles of 
TRIB2 may be due to the genetics of the AML subtype, 
the cancer type, and the profile of the apoptotic regulators 
within those cells.
In summary, elevated Trib2 expression conferred 
a drug resistant phenotype in AML which we have 
correlated with high Bcl2/BCL2 expression. Combined 
therapy using BCL2 inhibitors and standard chemotherapy 
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has potential to eradicate a clone of human AML cells that 
exhibits drug resistance, identifiable by high expression of 
BCL2 and TRIB2.
MATERIALS AND METHODS
Cell culture and fluorescence activated cell 
sorting (FACS)
NB4, HL-60 and U937 cell lines were maintained 
in RPMI plus 10% FBS, 1% Penicillin/Streptomycin/
Glutamine. Peripheral blood was isolated by tail vein nick 
or by cardiac puncture using 1ml insulin syringe. Long 
bones were removed and bone marrow (BM) cells were 
isolated by crushing in a pestle and mortar. In all tissues 
red blood cells (RBC) were lysed in RBC lysis buffer 
(155mM NH4Cl, 10mM KHCO3, 0.1mM EDTA). When 
isolating primary stem and progenitor populations, total 
BM cells were first MACS (Miltenyi) purified by lineage 
depletion (CD3, CD4, CD8, B220, CD11b, Gr1, Ter119). 
Cells were incubated and sorted with the appropriate 
antibodies; HSCs (Lin-cKit+Sca-1+CD150+CD48-), 
MPPs (Lin-cKit+Sca-1+CD150-CD48-), CMPs (Lin-
cKit+Sca-1-CD34+CD16/32+), GMPs (Lin-cKit+Sca-1-
CD34+CD16/32hi), and MEPs (Lin-cKit+CD34-CD16/32-). 
Sorting was performed using a BD FACS Aria II (BD 
Biosciences).
Trib2 transduction
PHR and PHR Trib2 lentivirus (SFFV promoter) or 
MigR1 and MigR1 Trib2 (MSCV promoter) retrovirus, 
as previously described and used interchangeably [35, 
41] were used to overexpress Trib2 in murine primary 
cells and human AML U937, HL60 and NB4 cell lines. 
pLKO.1 and pLKO.1 Trib2 lentivirus, as previously 
described [35], were used to knockdown Trib2 in human 
AML U937 cells. HEK293T packaging cell line were 
calcium phosphate transfected with retroviral or lentiviral 
expression plasmids, together with retroviral (pCGP, 
VSV-G) or lentiviral (psPax2, VSV-G) packaging vectors. 
Viral supernatants (sups) were harvested from the cells 
from 24-48 hours post transfection. Viral titres were 
determined by transducing 3T3 cells, and GFP expression 
was analysed 48 hours post transduction. All viral 
transductions were carried out in the presence of 4 mg/ml 
Polybrene. Suspension cells were spinoculated with virus 
and Polybrene at 1250g for 90 mins at RT. Cells were 
re-suspended in appropriate medium for 24 hrs before 
selection of GFP positive cells by FACS.
Murine BM transduction and transplantation
C57BL/6 (CD45.2+, B6) mice were purchased 
from Harlan UK or Charles River UK. B6.SJL-Ptprca/
BoyAiTac (CD45.1+, B6.SJL) mice bred and housed in the 
Beatson Biological Service and Research Units. All mouse 
experiments were approved by United Kingdom (UK) 
Animal Ethical Committees and performed according 
to UK Home Office project license 60/4512 (Animal 
Scientific Procedures Act 1986) guidelines. CD45.2+ 
BM (cKit enriched or sorted for stem and progenitor 
populations) cells were isolated from 6-8 weeks old mice, 
and transduced ex vivo with control or Trib2 virus in the 
presence of interleukin (IL)-3 (10 ng/ml), IL-6 (10 ng/
ml) and stem cell factor (100 ng/ml). Cells (1×106) were 
injected intravenously either 24 hours post transduction 
(HSPCs) or following CFC plating to P3 into lethally 
irradiated (2×4.25 grays fractionated doses were given 
three hours apart) or sublethally irradiated (1×4.5 grays) 
recipients CD45.1+. Mice were monitored by periodic tail 
vein bleedings three weeks after transplantation. Mice 
were euthanized when they showed clinical symptoms 
of disease (severe cachexia, lethargy, hunching) and/or 
elevated WBC counts, and elevating of leukaemic blasts.
Colony forming cell (CFC) assay
CFC replating assays are frequently used to 
determine if an oncogene confers self-renewal and 
proliferative potential to BM stem and progenitor cells in 
vitro. 24hours post-transduction of stem and progenitor 
populations, 5-20 × 104 transduced cells were resuspended 
in Methocult GF M3434 (Stem Cell Technologies) 
methylcellulose media and transferred to 3 × 35 mm 
culture dishes. Cells were incubated for 7-14 days before 
colonies were counted, scored and cells analysed by 
flow cytometry. To assess transformation of stem and 
progenitor populations, cells were continuously replated 
to P5. Trib2 expression in stem and progenitor populations 
was assessed in a representative set of transductions to 
confirm effective transgenesis (Supplementary Figure 1D).
Drug treatments
The cells were treated as indicated with cytarabine 
(Ara-C), Etoposide (Etop), doxorubicin (DOX), or 
daunorubicin (DNR) (Sigma-Aldrich), at the concentration 
indicated. The drugs were stored in DMSO. The BCL2 
inhibitor ABT199 was used at the concentrations 
indicated. The IC50 was experimentally determined as 
25.44 μM for PHR expressing cells and 14.07 μM for PHR 
Trib2 expressing cells.
Drug synergy studies and data analysis
U937 cells stably transduced with PHR or PHR 
Trib2 were treated with DNR or/and ABT199 and cell 
viability was determined using Annexin V and DAPI 
(Becton Dickinson, Oxford, UK) based flow cytometry 
analysis to determine live, apoptotic and necrotic cells. 
Single and combination drug effects were calculated as 
‘Fraction effected’ (Fa) of drug treated normalised to 
untreated cells. CompuSyn software [55] was used to 
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analyse dose dependent effect and evaluate drug synergy 
by calculation of combination index (CI). CI represents 
the degree of synergy or antagonism for any two drugs: 
CI ≥ 1 implies antagonism, CI = 0.9 to 1. additive effect, 
CI = 0.8 to 0.9 slight synergism, CI = 0.6 to 0.8 moderate 
synergism, CI = 0.4 to 0.6 synergism, and CI = 0.2 to 0.4 
strong synergism.
Cell lysate preparation
For total cell lysate, cells were lysed using RIPA 
lysis buffer (50 mM Tris-Hcl pH 7.4, 150 mM Nacl, 1% 
Triton x-100, 1% Sodium deoxycholate, 0.10% SDS, 1 
mM EDTA supplemented with protease and phosphatase 
inhibtors [1 mM phenylmethylsulfonyl fluoride (PMSF) 
(Sigma-Aldrich), 2 μg/ml aprotonin (Sigma- Aldrich), 
2 μg/ml leupeptin (Sigma-Aldrich), 1 μg/ml pepstatin A 
(Sigma- Aldrich), 1 mM sodium orthovanadate (Na3VO4) 
(Sigma-Aldrich) and 1 mM sodium fluoride (NaF) (Sigma-
Aldrich)] followed by incubation on ice for 30 mins. For 
mitochondrial and cytosolic fractionation, briefly, 5 × 106 
cells were washed in PBS and homogenized in a sucrose 
isolation buffer (10mM Tris–MOPS, 1mM EGTA/Tris, 
200mM sucrose, pH 7.4), with a Dounce homogeniser. 
The homogenised mix was then centrifuged at 600g for 
10min at 4°C. Supernatant (containing soluble cytoplasm 
and heavier membrane organelle) was collected and 
centrifuged at 7,000g for 10min at 4°C. The supernatant, 
which constitutes the cytoplasm and other heavy 
organelles, was collected as a separate fraction for further 
quantification and analysis. The pellet was separately 
washed and centrifuged at 7,000g for 10min at 4°C to 
obtain a pure pellet with mitochondria. It was then lysed 
using RIPA lysis buffer as above.
Western blotting
Western blotting was performed using antibodies 
against Trib2 (1:1000, Santa Cruz B-06, Germany) or 
in house anti TRIB2 (purified rabiit polyclonal, 1:1000, 
Patrick Eyers laboratory), BCL2 (1:2000, Cell Signalling), 
HSP70 (1:5000, Santa Cruz SC-66048), TOMM20 
(1:5000 Santa Cruz, SC-17764), β-ACTIN (1:10000 
Sigma A5541). Primary antibody detection was by 
enhanced chemiluminescence (GE Healthcare/Amersham) 
using horseradish peroxidase−linked secondary antibodies.
Real time quantitative PCR
Total RNA was extracted from cells using RNeasy® 
Mini Kit (Qiagen, UK) followed by first strand synthesis to 
cDNA using High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, UK). Transcript expression of 
various genes of interest was quantified using Fast SYBR® 
Green Master Mix (Applied Biosystems), on ABI 7900 
quantitative real time PCR machine. Primer sequences 
described in Supplementary Table 1.
Mitosis assay
For mitotic index measurement, the cells of interest 
were fixed using the BD Fixation/Permeabilization 
solution (BD biosciences) and permeabilised with 90% 
methanol, followed by incubation with anti-phospho-
Histone H3 antibody (pSER10-HH3). DNA staining was 
performed using DAPI. Flow cytometry analysis was 
performed using the FACS Canto cytometer (Becton 
Dickinson) and analysed using FlowJo (Tree Star 
Incorporation, Oregon, USA).
Statistics
GraphPad Prism (version 5.03) was used for 
statistical analysis and graphing. Statistical analyses were 
performed using the log-rang test and unpaired Student’s 
t test. Statistical significance was determined by a p value 
indicated as * (p ≤ 0.05), ** (p ≤ 0.01) and *** (p ≤ 0.001).
MILE data set analysis
We used the Microarray Innovations in Leukaemia 
dataset (MILE; GSE13204) [37] to assess the global gene 
expression of 2096 patients analysed using Affymetrix 
chips. Expression Console (Thermo-Fisher Scientific) 
was used for quality control and summarization of the 
probes’ intensities. The data was normalised using RMA. 
Gene expression of AML patients was compared with 
healthy individuals generating a p-value. All those genes 
presenting a p-value lower than 0.05 and an absolute 
fold change equal or greater than 2 were considered 
differentially expressed. To determine if BCL2 is 
commonly upregulated in AML patients with high 
expression of TRIB2 (the 25% of the samples with highest 
expression of TRIB2) the number of samples presenting 
high levels of expression of either of the genes (the 25% 
of the samples with highest expression of each gene) were 
compared. To test if this number was significant the gene 
expression values were permuted 10,000 times and the 
number of samples with high expression of both genes 
compared with the actual value (Monte-Carlo). Not a 
single permutation reached a higher number of samples 
than the actual one (p<0.0001). In order to validate 
this, the median BCL2 expression value of the samples 
expressing high TRIB2 was calculated (7.05) and using 
Monte-Carlo again not a single iteration out of 10,000 
reached the same expression value (p<0.0001).
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